Indapta Therapeutics is a biotechnology company founded in 2017, headquartered in the United States, and positioned at the forefront of developing a natural killer cell therapy with potent ADCC activity to combat cancer. Their allogeneic g-NK cells, known for their highly potent ADCC activity, are suitable for combination with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules. Their recent investment of $4.50M in the form of a grant, received on May 21, 2024, came from the Cancer Prevention and Research Institute of Texas.
Indapta Therapeutics
A biotechnology company focused on developing a natural killer cell therapy with potent ADCC activity to treat cancer.
Founded 2017
United States
14 employees
Unknown
Total: $77.00M
Biopharma, Biotechnology
United States
14 employees
Unknown
Total: $77.00M
Biopharma, Biotechnology
General Information
Get notified when Indapta Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Indapta Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biopharma
About Indapta Therapeutics
Taxonomy: Cancer therapy, Natural killer cells, ADCC activity, Allogeneic therapy, Monoclonal antibodies, ADCs, Innate immune cell engagers, Blood cancer, Solid tumor cancer, Cell therapy, Immuno-oncology, G-NK cells, Therapeutic antibodies, Biopharmaceuticals
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Early VC | •••••• | 5 |
|
01 Dec 2024 |
| Grant | •••••• | - | 01 May 2024 | |
| Series A | •••••• | 5 |
|
01 Feb 2022 |
| Unknown | •••••• | - | 01 Aug 2021 | |
| Seed | •••••• | - | 01 Dec 2019 |
Indapta Therapeutics Alternatives & Competitors
Indapta Therapeutics vs
ProMab Biotechnologies, Inc.
United States
Your Trusted Partner for Cutting-Edge Antibody, mRNA-LNP Solutions, and Immunotherapy Breakthroughs.
19 employees
Biotechnology
Indapta Therapeutics vs
Cytovia Therapeutics
United States
We empower Natural Killer cells to fight cancer through stem cell engineering and multispecific anti...
Unknown
6 employees
Biotechnology, Life Sciences
Indapta Therapeutics vs
Vor Bio
United States
Vor Bio's vision is to cure blood cancers through cell and genome engineering.
Post Ipo Equity
110 employees
Biotechnology, Health Care
FAQ About Indapta Therapeutics
A biotechnology company focused on developing a natural killer cell therapy with potent ADCC activity to treat cancer.
Indapta Therapeutics was founded in 2017.
Indapta Therapeutics is headquartered in United States.
Indapta Therapeutics operates in the following industries: Biopharma, Biotechnology.
Indapta Therapeutics has approximately 14 employees.
Indapta Therapeutics has completed 8 funding rounds, raising a total of $77.00M. The latest funding stage is Unknown.
Top alternatives and competitors to Indapta Therapeutics include ProMab Biotechnologies, Inc., Cytovia Therapeutics, Vor Bio, CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment, FREZENT Biological. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Indapta Therapeutics and ProMab Biotechnologies, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Don't just browse. Track.
Signal Tracker monitors Indapta Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.